Guangxi Liuzhou Pharmaceutical Co Ltd operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Guangxi Liuzhou Pharmaceutical Co Ltd with three other
drug stores in Asia:
Hokuyaku Takeyama Holdings, Inc
sales of 228.71 billion Japanese Yen [US$2.14 billion]
of which 70%
was Pharmaceutical Business),
Enseval Putera Megatrading Tbk PT
(19.67 trillion Indonesian Rupiahs [US$1.43 billion]
of which 43%
was Pharmaceuticals), and
Chuangmei Pharmaceutical Co Ltd
based in Hong Kong
(4.74 billion Hong Kong Dollars [US$603.20 million]
During the year ended December of 2017, sales at
Guangxi Liuzhou Pharmaceutical Co Ltd were 9.45 billion Chinese Renmimbi (US$1.50 billion).
increase of 25.0%
versus 2016, when the company's sales were 7.56 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Guangxi Liuzhou Pharmaceutical Co Ltd
(and since 2012, sales have increased a total of 166%).
Sales of Retail saw an increase
41.1% in 2017, from
615.06 million Chinese Renmimbi to 867.85 million Chinese Renmimbi.
Not all segments of Guangxi Liuzhou Pharmaceutical Co Ltd experienced an increase in sales in 2017:
sales of Others fell 59.3% to 1.37 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).